Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

503 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Blazing the trail for innovative tuberculosis diagnostics.
Yerlikaya S, Broger T, Isaacs C, Bell D, Holtgrewe L, Gupta-Wright A, Nahid P, Cattamanchi A, Denkinger CM. Yerlikaya S, et al. Among authors: isaacs c. Infection. 2024 Feb;52(1):29-42. doi: 10.1007/s15010-023-02135-3. Epub 2023 Nov 30. Infection. 2024. PMID: 38032537 Free PMC article. Review.
Innovative COVID-19 Point-of-Care Diagnostics Suitable for Tuberculosis Diagnosis: A Scoping Review.
Holtgrewe L, Jain S, Dekova R, Broger T, Isaacs C, Nahid P, Cattamanchi A, Denkinger CM, Yerlikaya S. Holtgrewe L, et al. Among authors: isaacs c. medRxiv [Preprint]. 2024 Jun 13:2024.06.13.24308880. doi: 10.1101/2024.06.13.24308880. medRxiv. 2024. Update in: J Clin Med. 2024 Oct 02;13(19):5894. doi: 10.3390/jcm13195894 PMID: 38947060 Free PMC article. Updated. Preprint.
Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer.
Prasath V, Boutrid H, Wesolowski R, Abdel-Rasoul M, Timmers C, Lustberg M, Layman RM, Macrae E, Mrozek E, Shapiro C, Glover K, Vater M, Budd GT, Harris L, Isaacs C, Dees C, Perou CM, Johnson GL, Poklepovic A, Chen H, Villalona-Calero M, Carson W, Stover DG, Ramaswamy B. Prasath V, et al. Among authors: isaacs c. Breast Cancer Res Treat. 2024 Dec 7. doi: 10.1007/s10549-024-07551-z. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 39644403
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer.
Rugo HS, Campbell M, Yau C, Jo Chien A, Wallace AM, Isaacs C, Boughey JC, Han HS, Buxton M, Clennell JL, Asare SM, Steeg K, Wilson A, Singhrao R, Matthews JB, Perlmutter J, Fraser Symmans W, Hylton NM, DeMichele AM, Yee D, Van't Veer LJ, Berry DA, Esserman LJ. Rugo HS, et al. Among authors: isaacs c. Breast Cancer Res Treat. 2024 Dec 3. doi: 10.1007/s10549-024-07555-9. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 39625569
Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial.
Huppert LA, Wolf D, Yau C, Brown-Swigart L, Hirst GL, Isaacs C, Pusztai L, Pohlmann PR, DeMichele A, Shatsky R, Yee D, Thomas A, Nanda R, Perlmutter J, Heditsian D, Hylton N, Symmans F, Van't Veer LJ, Esserman L, Rugo HS. Huppert LA, et al. Among authors: isaacs c. Ann Oncol. 2024 Oct 28:S0923-7534(24)04070-5. doi: 10.1016/j.annonc.2024.10.018. Online ahead of print. Ann Oncol. 2024. PMID: 39477071
Pharmacokinetics and pharmacogenomics of ribociclib in black patients with metastatic breast cancer the LEANORA study.
Schlam I, Smith DM, Peer C, Sissung T, Schmidt KT, Tan M, Chitalia A, Bishopric NH, Steinberg S, Choo-Wosoba H, Napoli G, Gallagher C, Ashai N, Whitaker K, Mainor C, Tiwari S, Swanson N, Malloy S, Isaacs C, Figg WD, Swain SM. Schlam I, et al. Among authors: isaacs c. NPJ Breast Cancer. 2024 Sep 30;10(1):84. doi: 10.1038/s41523-024-00692-w. NPJ Breast Cancer. 2024. PMID: 39349477 Free PMC article.
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
Shatsky RA, Trivedi MS, Yau C, Nanda R, Rugo HS, Davidian M, Tsiatis B, Wallace AM, Chien AJ, Stringer-Reasor E, Boughey JC, Omene C, Rozenblit M, Kalinsky K, Elias AD, Vaklavas C, Beckwith H, Williams N, Arora M, Nangia C, Roussos Torres ET, Thomas B, Albain KS, Clark AS, Falkson C, Hershman DL, Isaacs C, Thomas A, Tseng J, Sanford A, Yeung K, Boles S, Chen YY, Huppert L, Jahan N, Parker C, Giridhar K, Howard FM, Blackwood MM, Sanft T, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Symmans WF, Price E, Heditsian D, LeStage B, Perlmutter J, Pohlmann P, DeMichele A, Yee D, van 't Veer LJ, Hylton NM, Esserman LJ. Shatsky RA, et al. Among authors: isaacs c. Nat Med. 2024 Dec;30(12):3737-3747. doi: 10.1038/s41591-024-03267-1. Epub 2024 Sep 14. Nat Med. 2024. PMID: 39277672 Clinical Trial.
503 results